Equibles does not estimate personal net worth.
Get an email with a short summary when Inovio Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get INO alertsThe proxy statement of Inovio Pharmaceuticals, Inc. reports total compensation of $910,636 for Michael Sumner in fiscal 2025, including a base salary of $548,708. Disclosed compensation is on record for 2 fiscal years. Michael Sumner has spoken on 1 earnings call across 1 company, most recently for Inovio Pharmaceuticals, Inc. on March 12, 2026. Inovio Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Inovio Pharmaceuticals, Inc. includes Jacqueline E. Shea (CEO, COO and Board Member), Jacqueline Shea (CEO, COO and Board Member), Simon X. Benito (Chairman and Board Member) and 7 others.
“As Jackie outlined, we have made significant progress with our BLA, as outlined on this slide, including the acceptance of our file for review under the Accelerated Approval Program with a PDUFA date of October 30, 2026.”
Proxy statement
Start not stated–present
Last confirmed April 7, 2026
Biotechnology · Healthcare
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Inovio Pharmaceuticals, Inc. (INO) | M.D. Chief Medical Officer and Head of Development | $548,708 | $910,636 |
| 2024 | Inovio Pharmaceuticals, Inc. (INO) | M.D. Chief Medical Officer | $532,000 | $1,037,406 |
